PRIORITY PARTNERS
7231 Parkway Dr., Suite 100
Hanover, MD 21076

JOHNS HOPKINS
HEALTH PLANS

Prior Authorization

JOHNS HOPKINS HEALTH PLANS (MEDICAID)

Orilissa - Priority Partners MCO

This fax machine is located in a secure location as required by HIPAA regulations.
Complete/review information, sign and date. Fax signed forms to Johns Hopkins Health Plans at **1-410-424-4607**. Please contact Johns Hopkins Health Plans at **1-888-819-1043** with questions regarding the Prior Authorization process.
When conditions are met, we will authorize the coverage of Orilissa - Priority Partners MCO.

Drug Name (select from list of drugs shown)
Orilissa (elagolix)

Quantity Frequency Strength

Route of Administration Expected Length of Therapy

Patient Information
Patient Name: _____
Patient ID: _____
Patient Group No.: _____
Patient DOB: _____
Patient Phone:

Prescribing Physician
Physician Name: _____
Physician Phone: _____
Physician Fax: _____
Physician Address: _____
City, State, Zip: _____

Diagnosis: _____ **ICD Code:** _____

Comments: _____

Please circle the appropriate answer for each question.

1. Is this request for continuation of therapy? Y N

[Note: The use of physician samples, or manufacturer product discounts, does not guarantee coverage under the provisions of the medical and/or pharmacy benefit. All pertinent criteria must be met in order to be eligible for benefit coverage.]

[If no, then skip to question 5.]

2. Has the patient received the maximum recommended treatment course of 24 months? Y N

[If yes, then no further questions.]

3.	Does the patient have a coexisting condition of dyspareunia, or moderate hepatic impairment (Child-Pugh Class B)?	Y N
	[If yes, then no further questions.]	
4.	Is there documentation showing a reduction of dysmenorrhea and non-menstrual pelvic pain?	Y N
	[Note: Documentation must be submitted. Plan coverage is limited to a maximum total treatment duration of 24-months.]	
	[No further questions.]	
5.	Is the requested drug being prescribed by a gynecologist?	Y N
	[If no, then no further questions.]	
6.	Does the patient have any of the following: A) Pregnancy, B) Severe hepatic impairment (Child-Pugh C), C) Known osteoporosis, D) Concomitant use of strong organic anion transporting polypeptide (OATP) 1B1 inhibitors?	Y N
	[If yes, then no further questions.]	
7.	Is the patient 18 years of age or older?	Y N
	[If no, then no further questions.]	
8.	Is the requested drug being prescribed for management of moderate to severe pain associated with endometriosis?	Y N
	[Note: Documentation must be submitted.]	
	[If no, then no further questions.]	
9.	Does the patient have a documented trial and failure of at least two concurrent regimens consisting of a prescription strength nonsteroidal anti-inflammatory drug (NSAID) and a continuous (combination estrogen-progestin) hormonal contraceptive?	Y N
	[Note: Documentation must be submitted.]	
	[If no, then no further questions.]	
10.	Does the patient have liver disease?	Y N
	[If no, then no further questions.]	
11.	Does the patient have a documented Child-Pugh score of A or B?	Y N
	[Note: Documentation must be submitted.]	

I attest that the medication requested is medically necessary for this patient. I further attest that the information provided is accurate and true, and that the documentation supporting this information is available for review if requested by the claims processor, the health plan sponsor, or, if applicable a state or federal regulatory agency.

Prescriber (Or Authorized) Signature and Date